ophthalmology

News

FDA approves Regeneron's Eylea for diabetic retinopathy

Regeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the disease and reduce the risk of blindness.

News

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol

News

Novartis files potential blockbuster eye drug with FDA

Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD.

News

Novartis completes spin-out of Alcon eye unit

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.

News

Biogen buys UK gene therapy firm Nightstar for $800m

Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies for inherited retinal disorders, in a deal worth $800 million.

News

Verily/Google use algorithm to detect diabetic eye disease

Verily and Google have developed a machine learning algorithm that can automatically detect diabetes-related eye disease, which could be used to take pressure off services in countries wher

FDA approves Regeneron's Eylea for diabetic retinopathy

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Novartis files potential blockbuster eye drug with FDA

Novartis completes spin-out of Alcon eye unit

Biogen buys UK gene therapy firm Nightstar for $800m

Verily/Google use algorithm to detect diabetic eye disease

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

ophthalmology

Editor's Picks